ARWR — Advancing RNAi Therapies Across Multiple Disease MarketsArrowhead Pharmaceuticals, Inc.BATS:ARWRRichtv_officialArrowhead Pharmaceuticals ARWR is a leading RNA interference (RNAi) therapeutics company utilizing its proprietary TRiM™ platform to develop precision medicines targeting cardiometabolic, liver, pulmonary, and rare diseases. Key Catalysts: Commercial milestone with REDEMPLO®: The launch of REDEMPLO® (plozasiran) for familial chylomicronemia syndrome (FCS) marks Arrowhead’s transition into a commercial-stage biotechnology company, validating both its RNAi technology and development strategy. Major Phase 3 opportunities: Upcoming SHASTA-3 and SHASTA-4 Phase 3 trials in severe hypertriglyceridemia represent important regulatory and commercial catalysts that could significantly expand plozasiran’s addressable market. Deep metabolic disease pipeline: Arrowhead maintains a strong portfolio across obesity, MASH, metabolic disorders, and liver diseases, providing multiple potential value drivers. Promising early-stage candidates: Programs such as ARO-INHBE and ARO-ALK7 have demonstrated encouraging early data, supporting future opportunities in obesity and metabolic disease treatment. Platform diversification: The TRiM™ platform enables the company to efficiently develop targeted RNAi therapies across multiple therapeutic areas, reducing dependence on a single product. Investment Outlook: Bullish above: $63.00–$64.00 Upside target: $105.00–$110.00 Supported by commercial execution, late-stage clinical catalysts, and a diversified RNAi pipeline, Arrowhead is positioned as a leading player in next-generation genetic medicines. 📢 ARWR — Combining commercial momentum with a broad RNAi pipeline to drive the next phase of precision medicine.